Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
CytomX Therapeutics Inc is a biotechnology business based in the US. CytomX Therapeutics shares (CTMX) are listed on the NASDAQ and all prices are listed in US Dollars. CytomX Therapeutics employs 144 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $4.29 |
|---|---|
| 52-week range | $3.67 - $10.05 |
| 50-day moving average | $5.77 |
| 200-day moving average | $6.20 |
| Wall St. target price | $12.25 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.21 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.29 from 2022-01-21
| 1 week (2022-01-14) | 8.61% |
|---|---|
| 1 month (2021-12-23) | 1.66% |
| 3 months (2021-10-22) | -19.66% |
| 6 months (2021-07-23) | -22.70% |
| 1 year (2021-01-22) | -35.49% |
|---|---|
| 2 years (2020-01-23) | -44.14% |
| 3 years (2019-01-23) | 16.22 |
| 5 years (2017-01-23) | 11.57 |
| Revenue TTM | $66.2 million |
|---|---|
| Gross profit TTM | $100.4 million |
| Return on assets TTM | -12.1% |
| Return on equity TTM | -90.25% |
| Profit margin | -108.85% |
| Book value | $1.71 |
| Market capitalisation | $257.7 million |
TTM: trailing 12 months
We're not expecting CytomX Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, CytomX Therapeutics's shares have ranged in value from as little as $3.67 up to $10.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CytomX Therapeutics's is 0.5884. This would suggest that CytomX Therapeutics's shares are less volatile than average (for this exchange).
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc. , Bristol-Myers Squibb Company, ImmunoGen, Inc.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.